Abstract
In November 2009, the first cardiac catheterization laboratory in a cancer center in the world was opened at The University of Texas MD Anderson Cancer Center. With it surfaced a new field of interventional onco-cardiology. In 2016, an expert consensus from the Society for Cardiovascular Angiography and Interventions issued a landmark document encouraging interventional cardiologists to address the special considerations affiliated with onco-cardiology care. Cancer patients are excluded from most major trials with cardiovascular endpoints, resulting in a lack of guideline-based management. The systemic impact of malignancy determines a pro-inflammatory, prothrombotic state, which in turn leads to accelerated coronary artery disease and an increased risk of acute vascular events. The presence of thrombocytopenia or anemia may discourage invasive management. Conditions unique to this population arise, such as chemotherapy-induced Takotsubo cardiomyopathy or peripheral vascular disease, malignant pericardial effusions, or radiationinduced heart disease. The purpose of this chapter is to highlight the unique issues facing interventional onco-cardiologists and to present the available tools for optimizing cardiovascular care in cancer patients.
Original language | English (US) |
---|---|
Title of host publication | Oncologic Critical Care |
Publisher | Springer International Publishing |
Pages | 787-806 |
Number of pages | 20 |
ISBN (Electronic) | 9783319745886 |
ISBN (Print) | 9783319745879 |
DOIs | |
State | Published - Oct 12 2019 |
Keywords
- Cardio-oncology
- Device-based therapies
- Endomyocardial biopsy
- Interventional cardiology
- Percutaneous coronary intervention
- Pericardiocentesis
- Peripheral vascular disease
- Radiation-induced heart disease
- Structural valve disease
- Takotsubo cardiomyopathy
ASJC Scopus subject areas
- General Medicine